- CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that members of its executive leadership team have executed a second round of open market purchases of Prenetics common stock during ...

Rated the highest among 18 providers worldwide, Medidata is the only provider with 100% market adoption score for its end-to-end AI-powered solutions NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has secured the highest "Luminary" rating in Everest Group's 2026 Innovation Watch: AI Applications in Clinical Development. The ranking highlights the industry-leading impact of Medidata's experience- ...

New York, New York, March 03, 2026 (GLOBE NEWSWIRE) -- Antelope Enterprise Holdings Limited (NASDAQ: AEHL; the "Company" or "BIYA"), the majority interest owner of Kylin Cloud, a livestreaming e- commerce business in China, is reporting that its board of directors has approved a reverse stock split (the "Reverse Stock Split") of the Company's class A ordinary shares (the "Ordinary Shares"), at a ratio of 1-for-6. The Reverse Stock Split will be effective at 04:01 p.m. (ET) on Wednesday, March 4, 2026 (the " ...

Core Insights - LivePerson has launched Syntrix, a simulation and evaluation platform aimed at helping enterprises confidently deploy customer-facing AI and enhance customer interactions with both AI and live agents [1][2] Group 1: Syntrix Overview - Syntrix is designed to provide brands with the assurance needed to deploy customer-facing AI safely, offering visibility, control, and confidence to scale operations [2] - The platform allows brands to transition from reactive learning to proactive simulation and continuous evaluation, ensuring strong governance practices and meaningful business outcomes [2][3] Group 2: Operational Impact - Early estimates indicate that Syntrix can significantly impact operational efficiency for enterprise brands [3] - The platform enables continuous stress-testing of AI agents against diverse customer personas and edge-case scenarios, ensuring predictable performance regardless of the underlying AI model [5] Group 3: Training and Cost Efficiency - Syntrix replaces traditional manual role-playing for live agent training with scalable AI-powered simulations, allowing new hires to practice complex conversations and receive instant feedback on performance metrics [5] - The platform can reduce new hire ramp time by up to 30% and save an average of $3,500 in onboarding costs per agent [5] Group 4: Future Developments - The launch of Syntrix marks the first phase of a broader platform, with plans for future enhancements that will include advanced intelligence for automating analysis and preventing customer experience failures [3]

Group 1 - The focus is on income-producing asset classes such as REITs, ETFs, Preferreds, and 'Dividend Champions' that target premium dividend yields up to 10% [1][3] - iREIT®+HOYA Capital is highlighted as a premier income-focused investing service that offers sustainable portfolio income, diversification, and inflation hedging [2][3] - The investment research provided includes strategies for trading options and emphasizes dependable monthly income and portfolio diversification [3] Group 2 - The service offers a Free Two-Week Trial for potential investors to explore top ideas across exclusive income-focused portfolios [2] - The articles aim to assist individuals in preparing for retirement through investments in various asset classes including CEFs, ETFs, BDCs, and REITs [3]

Following the conference call, a replay will be available via webcast at https://ir.comscore.com/events- presentations. About Comscore Comscore is a global, trusted partner for planning, transacting and evaluating media across platforms. With an unmatched data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore empowers media buyers and sellers to quantify their multiscreen behavior and make meaningful business decisions w ...

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Antimony Resources Corp. (CSE: ATMY) (OTCQB: ATMYF) (FSE: K8J0) (the "Company" or "Antimony Resources" or "ATMY") is pleased to announce that the current 10,000 meter drill program is underway and is continuing to intersect massive antimony-bearing stibnite mineralization on the Main zone.HighlightsDrilling on the Main Zone is continuing with drills intersecting massive antimony- bearing stibnite mineralization from both the East and West Side ...

"Our presence on Walmart, alongside Amazon and Chewy, completes a vital retail triangle for us," said Zach O'Shea, CEO of NDT Pharmaceuticals. "We viewed the close of Q4 as a period of significant strategic energy, and that momentum has carried into the first two months of 2026. As consumers increasingly prioritize non-toxic, professional-grade solutions for their homes and pets, we have taken the steps that we believe are necessary to position our brand exactly where they are looking to discover new produc ...

– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan – STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, an entrepreneur, ...

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) ("iMDx") today announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification. Beginning in 2026, iMDx seeks to deliver the industry-leading molecular diagnostic test kit for clinical use th ...